Graft

ISHLT Honors Hannah Valantine for Lifetime Achievement in Treating Advanced Heart Disease

Retrieved on: 
Thursday, April 28, 2022
Solution, National, Medicine, DNA, International Society for Heart and Lung Transplantation, Family, Leadership, National academy, Heart transplantation, National Academy of Medicine, Patient, Female, Cardiology, Movement, Education, Faculty, Journal, List of lifetime achievement awards, Diversity, Annual general meeting, Mentorship, BPS Barbara Wilson Lifetime Achievement Award, Quality of life, Cardiac allograft vasculopathy, Disease, Graft, Cytomegalovirus, Dean (education), Stanford University, Element, Diagnosis, Senior, Woman, Multimedia, Science, The Journal of Heart and Lung Transplantation, International Society, Research, DRS, National Heart, Lung, and Blood Institute, Organ transplantation, Lung, NIH, MBBS, Health, Lung transplantation, Medical device, Dentistry, Heart, MD, Transplant, University of London

BOSTON, April 28, 2022 /PRNewswire/ -- During its 42nd Annual Meeting in Boston, the International Society of Heart and Lung Transplantation honored the recipient of the 2022 Lifetime Achievement Award, Hannah Valantine, MD, MBBS.

Key Points: 
  • BOSTON, April 28, 2022 /PRNewswire/ -- During its 42nd Annual Meeting in Boston, the International Society of Heart and Lung Transplantation honored the recipient of the 2022 Lifetime Achievement Award, Hannah Valantine, MD, MBBS.
  • "I am deeply honored to receive this receive this Lifetime Achievement Award from the ISHLT," Dr. Valantine said.
  • The Lifetime Achievement Award was formally presented during a plenary session, Thursday, 28 April.
  • ISHLT Board member Kiran Khush, MD, who works with Dr. Valantine at Stanford University, presented the award.

Orthofix Announces US Launch and First Patient Implants with New fiberFUSE Strip – An Advanced Fiber Bone-Graft Solution Containing Cancellous Bone

Retrieved on: 
Wednesday, July 28, 2021
Medical devices, Surgery, Medical Supplies, Hospitals, FDA, Clinical trials, Practice Management, Biotechnology, Pharmaceutical, Health, Medical specialties, Clinical medicine, Medicine, Transplantation medicine, Skeletal system, Graft, Surgery, Bone, Allotransplantation, Bone grafting, Orthofix, MTF Biologics, ORTHOFIX, MTF BIOLOGICS

(NASDAQ:OFIX), a global medical device company with a spine and orthopedics focus, today announced the launch and first patient implants with the fiberFUSE Strip , an advanced demineralized fiber bone-graft solution containing cancellous bone.

Key Points: 
  • (NASDAQ:OFIX), a global medical device company with a spine and orthopedics focus, today announced the launch and first patient implants with the fiberFUSE Strip , an advanced demineralized fiber bone-graft solution containing cancellous bone.
  • View the full release here: https://www.businesswire.com/news/home/20210728005105/en/
    Image of the Orthofix fiberFUSE Strip, an advanced demineralized fiber bone-graft solution containing cancellous bone.
  • We are pleased to introduce this next-generation formulation in the fiberFUSE allograft line, said Kevin Kenny, President of Orthofix Global Spine.
  • The fiberFUSE Strip delivers a high-quality advanced bone-graft option in a convenient, easy-to-use strip preparation.

MIMEDX to Host Second Quarter 2021 Operating and Financial Results Conference Call on August 4

Retrieved on: 
Tuesday, July 20, 2021
Medical specialties, Medicine, Clinical medicine, Transplantation medicine, Allotransplantation, Immunology, Regenerative biomedicine, MiMedx, Graft, Sterilization

MIMEDX is an industry leader in utilizing amniotic tissue as a platform for regenerative medicine, developing and distributing placental tissue allografts with patent-protected, proprietary processes for multiple sectors of healthcare.

Key Points: 
  • MIMEDX is an industry leader in utilizing amniotic tissue as a platform for regenerative medicine, developing and distributing placental tissue allografts with patent-protected, proprietary processes for multiple sectors of healthcare.
  • We derive our products from human placental tissues and process these tissues using our proprietary methods, including the PURION process.
  • We employ Current Good Tissue Practices, Current Good Manufacturing Practices, and terminal sterilization to produce our allografts.
  • MIMEDX has supplied over two million allografts, through both direct and consignment shipments.

Global Soft Tissue Allografts Market (2021 to 2026) - Growing Economic Benefits of Organ and Tissue Transplants Presents Opportunities - ResearchAndMarkets.com

Retrieved on: 
Friday, July 16, 2021
Surgery, Health, Transplantation medicine, Graft, Allotransplantation

The "Global Soft Tissue Allografts Market 2021-2026" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Soft Tissue Allografts Market 2021-2026" report has been added to ResearchAndMarkets.com's offering.
  • The global market for soft tissue allografts should grow from $5.1 billion in 2021 to $6.6 billion by 2026, at compound annual growth rate (CAGR) of 5.3% for the period of 2021-2026.
  • The report will provide details about the soft tissue allografts used in the treatment of dental disease, facial dental surgery, orthopedic surgery, and other surgical processes.
  • It will also highlight the current and future market potentiality of soft tissue allografts with detailed analysis of the competitive environment.

Bioventus Launches OSTEOAMP® SELECT Flowable Nationwide

Retrieved on: 
Tuesday, July 13, 2021
Medical specialties, Clinical medicine, Medicine, Transplantation medicine, Spinal fusion, Bone grafting, Allotransplantation, Vertebral column, Graft, Flowable

DURHAM, N.C., July 13, 2021 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (Bioventus or the Company), a global leader in innovations for active healing, is launching OSTEOAMP SELECT Flowable, a flowable allograft bone graft substitute solution developed for a variety of patient procedures including lumbar spine fusion, cervical spine fusion and foot & ankle fusion.

Key Points: 
  • DURHAM, N.C., July 13, 2021 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (Bioventus or the Company), a global leader in innovations for active healing, is launching OSTEOAMP SELECT Flowable, a flowable allograft bone graft substitute solution developed for a variety of patient procedures including lumbar spine fusion, cervical spine fusion and foot & ankle fusion.
  • Developed by our team in collaboration with our tissue bank partner, OSTEOAMP SELECT Flowable comes ready-to-use, and is designed to be delivered in a range of methods, and to provide excellent retention characteristics at the grafting site.
  • OSTEOAMP SELECT Flowable comes in three sizes from 2.5 to 10 cc and is available nationwide.
  • OSTEOAMP, Bioventus and the Bioventus logo are registered trademarks of Bioventus LLC.

Mallinckrodt Announces Publication of Phase 3 STRATA2016 Study in Burns

Retrieved on: 
Wednesday, July 7, 2021
Medical specialties, Medicine, Clinical medicine, Transplantation medicine, Acute pain, Burn, Heat transfer, Autotransplantation, Graft

"We were encouraged to see in the Phase 3 trial that treatment with StrataGraft eliminated donor tissue harvest in all but three of the 71 study participants.

Key Points: 
  • "We were encouraged to see in the Phase 3 trial that treatment with StrataGraft eliminated donor tissue harvest in all but three of the 71 study participants.
  • Results published in Burns showed the study met its co-primary efficacy endpoints of autograft sparing and durable wound closure by three months.
  • The trial sites involved in the pivotal Phase 3 trial (STRATA2016, NCT03005106 ) have the opportunity to participate in this multicenter, open-label study.
  • The company is planning to evaluate StrataGraftfor the treatment of adults with full-thickness burns (also referred to as third-degree burns).

Biogennix Celebrates a Decade of Innovation and Clinical Success

Retrieved on: 
Tuesday, June 29, 2021
Medical Supplies, Health, Hospitals, Surgery, Manufacturing, Other Manufacturing, Biotechnology, Medical specialties, Clinical medicine, Surgery, Transplantation medicine, Bone grafting, Oral and maxillofacial surgery, Spinal fusion, Bone, Graft

In 2011, Biogennix introduced its novel osteoSPAN fusion kits , which consist of two uniquely-sized porous blocks designed to span the transverse processes during single-level spine fusion procedures.

Key Points: 
  • In 2011, Biogennix introduced its novel osteoSPAN fusion kits , which consist of two uniquely-sized porous blocks designed to span the transverse processes during single-level spine fusion procedures.
  • Its been a highly rewarding ten years of seeing positive clinical outcomes and receiving enthusiastic feedback from surgeons for each of our products, said Dr. Edwin Shors, President of Biogennix.
  • Biogennix is a fully-integrated osteobiologics company headquartered in Irvine, CA which develops, manufactures, and distributes proprietary bone grafting products used in bone fusion procedures.
  • Biogennix is committed to advancing technology behind next-generation bone grafting solutions, delivering outstanding quality with exceptional value, and customer-focused excellence.

MIMEDX to Present at the Raymond James 2021 Human Health Innovation Conference

Retrieved on: 
Wednesday, June 16, 2021
Medical specialties, Medicine, Clinical medicine, Transplantation medicine, Regenerative biomedicine, Allotransplantation, Immunology, MiMedx, Sterilization, Graft

A live webcast of the presentation will be available on the Events page of the Investors section of the Companys website at www.mimedx.com or through the conference site by using the link above.

Key Points: 
  • A live webcast of the presentation will be available on the Events page of the Investors section of the Companys website at www.mimedx.com or through the conference site by using the link above.
  • We derive our products from human placental tissues and process these tissues using our proprietary methods, including the PURION process.
  • We employ Current Good Tissue Practices, Current Good Manufacturing Practices, and terminal sterilization to produce our allografts.
  • MIMEDX has supplied over two million allografts, through both direct and consignment shipments.

FDA Approves StrataGraft for the Treatment of Adults with Thermal Burns

Retrieved on: 
Tuesday, June 15, 2021
Medical specialties, Clinical medicine, Medicine, Acute pain, Medical emergencies, Plastic surgery, Skin grafting, Graft, Burn, Wound, Thermal burn, Artificial skin

For many deep burns, treatment frequently involves the removal of the damaged, burned skin and replacement with a skin graft.

Key Points: 
  • For many deep burns, treatment frequently involves the removal of the damaged, burned skin and replacement with a skin graft.
  • Treatment with StrataGraft can help avoid or decrease the amount of healthy skin that is needed for grafting.
  • The effectiveness and safety of StrataGraft are based on two randomized clinical studies involving a total of 101 adult patients with deep partialthickness thermal burns.
  • The effectiveness is demonstrated by the percentage of StrataGraft treatment sites that achieved a complete wound closure, and the significantly decreased need for autografts at the StrataGraft treatment sites.

U.S. Food and Drug Administration Approves Expanded Use of the RECELL® System for the Treatment of Extensive Burns and Pediatric Patients

Retrieved on: 
Thursday, June 10, 2021
Medical specialties, Medicine, Burns, Health, Avita Medical, Pediatrics, Pediatric burn, Biomedical Advanced Research and Development Authority, Food and Drug Administration, Graft, Avita, Thermal burn

In addition, the indication now includes treatment for full-thickness thermal burns that extend beyond 50% total body surface area (TBSA).

Key Points: 
  • In addition, the indication now includes treatment for full-thickness thermal burns that extend beyond 50% total body surface area (TBSA).
  • BARDA and AVITA Medical have decided to stop recruitment for the ongoing pediatric burn study and follow currently enrolled patients for 12 months in alignment with the study protocol.
  • RECELL significantly reduced the mean number of pediatric grafting procedures compared to the National Burn Repository (1.6 treatments vs 3.6 treatments, respectively).
  • AVITA Medicals first U.S. product, the RECELLSystem, was approved by the U.S. Food and Drug Administration (FDA) in September 2018.